Quick Facts at a Glance
- Recall Date
- July 9, 2025
- Hazard Level
- HIGH
- Brand
- Boothwyn Pharmacy
- Category
- Health & Personal Care
- Sold At
- Unknown
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL, PREGNANT, ELDERLY
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- Boothwyn Pharmacy
- Product type
- Semaglutide Injection
- Model numbers
- 03202025@9 BUD 07/18/2025
- Sizes
- 0.8 mL
- Sold at
- Unknown
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
July 9, 2025
Reported by FDA DRUG
September 10, 2025
RecallRadar source check
April 18, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Subpotent Drug
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
About This Product
Semaglutide is a prescription GLP-1 receptor agonist used for glycemic control in type 2 diabetes and obesity management.
Why This Is Dangerous
Subpotent drug may lead to reduced efficacy, potential poor disease management, and need for medical reassessment.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers and healthcare providers must halt use and await guidance; potential impact includes treatment disruption and need for alternative therapies.
Practical Guidance
How to identify if yours is affected
- Locate model number on the vial label: 03202025@9 BUD 07/18/2025
- Check packaging for lot numbers and dates if available
- Verify that the product is labeled Semaglutide 2.5 mg/mL injection, 0.8 mL
Where to find product info
FDA recall page D-0608-2025 for Boothwyn Pharmacy enforcement notice
What timeline to expect
Refund or replacement details to be issued by Boothwyn Pharmacy as recall progresses
If the manufacturer is unresponsive
- Document all attempts to contact Boothwyn Pharmacy
- File a consumer complaint with FDA if Boothwyn is unresponsive
How to prevent similar issues
- Always verify drug potency with pharmacist before use
- Watch for recall notices from pharmacies and manufacturers
- Keep prescription records and batch/lot numbers secure
Documentation advice
Keep recall notification, packaging, receipts, and correspondence as records
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
Model numbers: 03202025@9 BUD 07/18/2025. Quantity: 186 vials. Distribution: U.S. nationwide. Sold by Boothwyn Pharmacy. Recall date: 2025-07-09. Status: ACTIVE.
Reported Incidents
No specific injuries or incidents are listed in the provided data.
Key Facts
- Subpotent drug (Class II)
- Active status as of 2025-09-10
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.